ABSTRACT
Purpose
The prognosis for glioma patients is poor, and development of new treatments is critical. Previously, we engineered polymer-based vaccines that control GM-CSF, CpG-oligonucleotide, and tumor-lysate presentation to regulate immune cell trafficking and activation, which promoted potent immune responses against peripheral tumors. Here, we extend the use of this system to glioma.
Methods
Rats were challenged with an intracranial injection of glioma cells followed (1 week) by administration of the polymeric vaccine (containing GM-CSF, CpG, and tumor-lysate) in the tumor bed. Control rats were treated with blank matrices, matrices with GM-CSF and CpG, or intra-tumoral bolus injections of GM-CSF, CpG, and tumor lysate. Rats were monitored for survival and tested for neurological function.
Results
Survival studies confirmed a benefit of the polymeric vaccine as 90% of vaccinated rats survived for >100 days. Control rats exhibited minimal benefit. Motor tests revealed that vaccination protected against the loss of forelimb use produced by glioma growth. Histological analysis quantitatively confirmed a robust and rapid reduction in tumor size. Long-term immunity was confirmed when 67% of survivors also survived a second glioma challenge.
Conclusions
These studies extend previous reports regarding this approach to tumor therapy and justify further development for glioma treatment.
This is a preview of subscription content, log in via an institution to check access.
Similar content being viewed by others
REFERENCES
Legler JM, Gloeckler Ries LA, Smith MA, Warren JL, Heineman EF, Kaplan RS, Linet MS. Brain and other central nervous system cancers: recent trends in incidence and mortality. J Natl Cancer Inst. 1999;1382–90.
Okada H. Brain tumor immunotherapy with type-1 polarizing strategies. Ann NY Acad Sci. 2009;1174:18–23.
Grauer OM, Molling JW, Benniink E, Toonen LW, Sutmuller RP, Nierkens S, et al. TLR ligands in the local treatment of established intracerebral murine gliomas. J Immunol. 2008;181:6720–9.
Grauer OM, Wesseling P, Adema GJ. Immunotherapy of diffuse gliomas: biological background, current status and future developments. Brain Pathol. 2009;19:674–93.
Banchereau J, Steinman RM. Taking dendritic cells into medicine. Nature. 2007;49:419–26.
Holger K, Frank B, Hessel E, Coffman RL. Therapeutic targeting of innate immunity with Toll-like receptor agonists and antagonists. Nat Med. 2007;13:552–9.
Nair RE, Jong YS, Jones SA, Sharma A, Mathiowitz E, Egilmez NK. IL-12 + GM-CSF microsphere therapy induces eradication of advanced spontaneous tumors in her-2/neu transgenic mice but fails to achieve long-term cure due to the inability to maintain effector T-cell activity. J Immunother. 2006;29:10–20.
Yu JS, Liu G, Ying H, Yong WH, Black KL, Wheeler CJ. Vaccination with tumor lysate-pulsed dendritic cells elicits antigen specific cytotoxic T cells in patients with malignant glioma. Cancer Res. 2004;64:4973–9.
Gilboa E. Dendritic cell based vaccines. J Clin Invest. 2007;117:1195–203.
Yamanaka R, Abe T, Yajima N, Tsuchiya N, Homma J, Kobayashi T, et al. Vaccination of recurrent glioma patients with tumour lysate-pulsed dendritic cells elicits immune responses: results of a clinical phase I/II trial. Br J Cancer. 2003;89:1172–9.
Ingram M, Buckwalter JG, Jacques DB, Freshwater RM, Abts GB, Techy K, et al. English, Immunotherapy for recurrent malignant glioma: an interim report on survival. Neurol Res. 1990;12:265–73.
Allen TM, Cullis PR. Drug delivery systems: entering the mainstream. Science. 2004;303:1818–22.
Brem H, Piantadosi S, Burger PC, Walker M, Selker R, Vick NA, et al. Placebo-controlled trial of safety and efficacy of intraoperative controlled delivery by biodegradable polymers of chemotherapy for recurrent gliomas. Lancet. 1995;345:1008–12.
Ali OA, Huebsch N, Cao L, Dranoff G, Mooney DJ. Infection-mimicking materials to program dendritic cells in situ. Nat Mater. 2009;2:151–8.
Ali OA, Emerich D, Dranoff G, Mooney DJ. In Situ regulation of DC subsets and T Cells mediates tumor regression in mice. Sci Transl Med. 2009;1:8–19.
Cohen S, Yoshioka T, Lucarelli M, Hwang LH, Langer R. Controlled delivery systems for proteins based on poly(lactic/glycolic acid) microspheres. Pharm Res. 1991;8:713–20.
Richardson TP, Peters MC, Ennett AB, Mooney DJ. Polymeric system for dual growth factor delivery. Nat Biotechnol. 2001;19:1029–34.
Emerich DF, Mooney DJ, Storrie H, Babu RS, Kordower JH. Injectable hydrogels providing sustained delivery of vascular endothelial growth factor are neuroprotective in a rat model of Huntington's disease. Neurotox Res. 2010;1:66–74.
Morrone FB, Oliveira DL, Gamermann P, Stella J, Wofchuk S, Wink MR, Meurer L, Edelweiss MI, Lenz G, Battastini AM. In vivo glioblastoma growth is reduced by apyrase activity in a rat glioma model. BMC Cancer. 2006;226–32.
Gu F, Younes HM, El-Kadi AO, et al. Sustained interferon-gamma delivery from a photocrosslinked biodegradable elastomer. JCR. 2005;102(3):607–17.
Zaharoff DA, Hoffman BS, Hooper HB, et al. Intravesical immunotherapy of superficial bladder cancer with chitosan/interleukin-12. Cancer Res. 2009;69:6192–9.
Neelapu SS, Baskar S, Gause BL, et al. Human autologous tumor-specific T-Cell responses induced by liposomal delivery of a lymphoma antigen. Clin Cancer Res. 2004;24:8309–17.
Hubbell JA, Thomas SN, Swartz MA. Materials engineering for immunomodulation. Nature. 2009;462:449–60.
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Ali, O.A., Doherty, E., Bell, W.J. et al. Biomaterial-Based Vaccine Induces Regression of Established Intracranial Glioma in Rats. Pharm Res 28, 1074–1080 (2011). https://doi.org/10.1007/s11095-010-0361-x
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s11095-010-0361-x